# Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

> **NCT02723578** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 50 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02723578
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-01
- **Primary completion:** 2018-08
- **Final completion:** 2018-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723578, "Pemetrexed and Erlotinib for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02723578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*